ASTEPRO 0.15% Rx
Generic Name and Formulations:
Azelastine HCl 0.15% (205.5mcg/spray;) aqueous nasal spray; contains benzalkonium chloride.
Indications for ASTEPRO 0.15%:
Seasonal and perennial allergic rhinitis.
Seasonal: 1 or 2 sprays in each nostril twice daily or 2 sprays in each nostril once daily. Perennial: 2 sprays in each nostril twice daily.
Avoid eyes, mouth. Pregnancy (Cat.C). Nursing mothers.
Potentiates CNS depression with alcohol, other CNS depressants. Caution with other antihistamines.
Bitter taste, nasal discomfort, epistaxis, headache, fatigue, somnolence, sneezing.
Spray—17mL (106 sprays), 30mL (200 sprays)
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- The Caregivers' Cancer Journey
- Staff Education Leads to Increase in Oncology Rehabilitation Referrals
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Gender Bias in Medicine Has Far-Reaching Consequences
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Patient Interest in Melanoma Genetic Risk Testing is Fairly High
- Genetic Link Between Depression and Breast Cancer Remains Unclear
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|